



For More Information Contact:

Jim Rex

President

jrex@theghtcompanies.com

(858) 740-6919

Ingredient

Lactic Acid Bacterium LJ88®

LJ88® (*Lactobacillus johnsonii* #1088) is a heat-killed lactic acid bacterium isolated from the human stomach - a highly acid-resistant strain uniquely suited for gastric and intestinal health applications. Its native gastric origin provides exceptional survivability and compatibility within the human gastrointestinal tract, outperforming traditional probiotics not adapted to acidic environments.

Key Highlights

Functional Benefits

- **Dual-Region Efficacy:** Demonstrated benefits across both stomach and intestinal environments.
- **Gastrin Regulation:** Shown to suppress excessive gastrin production resulting in reduced gastric acid secretion.
- **Clinically Observed Symptom Reduction:** Demonstrated improvements in GERD-related discomfort.
- **H. pylori Inhibition:** Reduces colonization potential, supporting healthy gastric mucosa
- **Microbiome Support:** Promotes beneficial Bifidobacteria growth in the intestinal tract.

Postbiotic Advantages for Formulation

- **Heat-Killed Stability** — maintains biological efficacy without viability risks.
- **Flexible Application** — Capsules, tablets, powders and functional foods.
- **Safety Confirmed** — Non-pathogenic, no antibiotic resistance or gene transfer risk.
- **Global Regulatory Acceptance** — launched in 10+ countries since 2016, no adverse events reported.

Shelf Life

- **Room-Temperature Stable** — 5-year shelf life, no cold storage required.

Patented

Patented in Japan, Korea and the United States

Country of Origin

Japan

Formulation Opportunity

LJ88® delivers a stable, scientifically validated solution for digestive health formulations seeking differentiation through proven mechanisms, long shelf stability, and global regulatory precedents.

Partner with
The GHT Companies —
**Translating scientific
discovery into business
enterprise.**

Founding Scientist

